Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.

Xiuning Le,Curtis R. Pickering,M. Laura Rubin,Frederico Netto,Merrill S. Kies,Faye M. Johnson,Charles Lu,George R. Blumenschein,Diana Bell,Lawrence E. Ginsberg,Kaye F Wilson,Jeff Lewis,Lei Feng,Jing Wang,J. Jack Lee,William N. William,Jeffrey N. Myers

Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection.

2019

Xiuning Le
Curtis R. Pickering
M. Laura Rubin
Frederico Netto
Merrill S. Kies
Faye M. Johnson
Charles Lu
George R. Blumenschein
Diana Bell
Lawrence E. Ginsberg
Kaye F Wilson
Jeff Lewis
Lei Feng
Jing Wang
J. Jack Lee
William N. William
Jeffrey N. Myers

6067Background: We have previously demonstrated activity of erlotinib in head and neck SCCs as monotherapy prior to surgical resection, or in combination with chemotherapy for recurrent/metastatic ...

Keywords:

Erlotinib
Cell
Induction chemotherapy
Pathology
Oncology
Medicine
Internal medicine
Resection
in patient
oral cavity
surgical resection
Chemotherapy
head and neck
Radiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations